A step forward in the diagnosis of B-cell lymphomas in the bone marrow

Ahmet Dogan, Mine Hekimgil, Nazan Ozsan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and monitoring of non-Hodgkin lymphomas (NHL). This chapter will deal with the current investigations focusing on the BM findings in secondary involvement of B-cell lymphomas. Recent World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues includes morphologic, immunophenotypic, cytogenetic, and molecular genetic data that define the disease entities [1]. Each entity described in this chapter will be discussed on the basis of a combination of these studies used in routine diagnosis of lymphoid malignancies. BM is occasionally examined for primary diagnosis of lymphoma patients, initial assessment of cytopenias of unknown etiology, especially when there's no accessible site of extramedullary disease or when surgical procedures are risky because of hazardous complications of anesthesia due to the general condition of the patients or diseases leading to bleeding diathesis. However, most BM examination, in the context of NHL, are performed to determine stage of disease, assessment of minimal residual disease (MRD) or relapse during follow-up, monitoring response to therapy, evaluation of hematopoietic reserve, and evaluation of pre-transplant status of patients.

Original languageEnglish (US)
Title of host publicationBone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact
PublisherSpringer-Verlag London Ltd
Pages191-221
Number of pages31
Volume9781447141747
ISBN (Print)9781447141747, 1447141733, 9781447141730
DOIs
StatePublished - Nov 1 2012

Fingerprint

B-Cell Lymphoma
Bone Marrow
Bone Marrow Examination
Non-Hodgkin's Lymphoma
Disease Susceptibility
Residual Neoplasm
Lymphoid Tissue
Cytogenetics
Molecular Biology
Lymphoma
Neoplasms
Anesthesia
Hemorrhage
Transplants
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dogan, A., Hekimgil, M., & Ozsan, N. (2012). A step forward in the diagnosis of B-cell lymphomas in the bone marrow. In Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact (Vol. 9781447141747, pp. 191-221). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4174-7_11

A step forward in the diagnosis of B-cell lymphomas in the bone marrow. / Dogan, Ahmet; Hekimgil, Mine; Ozsan, Nazan.

Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact. Vol. 9781447141747 Springer-Verlag London Ltd, 2012. p. 191-221.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dogan, A, Hekimgil, M & Ozsan, N 2012, A step forward in the diagnosis of B-cell lymphomas in the bone marrow. in Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact. vol. 9781447141747, Springer-Verlag London Ltd, pp. 191-221. https://doi.org/10.1007/978-1-4471-4174-7_11
Dogan A, Hekimgil M, Ozsan N. A step forward in the diagnosis of B-cell lymphomas in the bone marrow. In Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact. Vol. 9781447141747. Springer-Verlag London Ltd. 2012. p. 191-221 https://doi.org/10.1007/978-1-4471-4174-7_11
Dogan, Ahmet ; Hekimgil, Mine ; Ozsan, Nazan. / A step forward in the diagnosis of B-cell lymphomas in the bone marrow. Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact. Vol. 9781447141747 Springer-Verlag London Ltd, 2012. pp. 191-221
@inbook{35b6c7cd9c57450789dfe851261eeaa9,
title = "A step forward in the diagnosis of B-cell lymphomas in the bone marrow",
abstract = "Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and monitoring of non-Hodgkin lymphomas (NHL). This chapter will deal with the current investigations focusing on the BM findings in secondary involvement of B-cell lymphomas. Recent World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues includes morphologic, immunophenotypic, cytogenetic, and molecular genetic data that define the disease entities [1]. Each entity described in this chapter will be discussed on the basis of a combination of these studies used in routine diagnosis of lymphoid malignancies. BM is occasionally examined for primary diagnosis of lymphoma patients, initial assessment of cytopenias of unknown etiology, especially when there's no accessible site of extramedullary disease or when surgical procedures are risky because of hazardous complications of anesthesia due to the general condition of the patients or diseases leading to bleeding diathesis. However, most BM examination, in the context of NHL, are performed to determine stage of disease, assessment of minimal residual disease (MRD) or relapse during follow-up, monitoring response to therapy, evaluation of hematopoietic reserve, and evaluation of pre-transplant status of patients.",
author = "Ahmet Dogan and Mine Hekimgil and Nazan Ozsan",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/978-1-4471-4174-7_11",
language = "English (US)",
isbn = "9781447141747",
volume = "9781447141747",
pages = "191--221",
booktitle = "Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - A step forward in the diagnosis of B-cell lymphomas in the bone marrow

AU - Dogan, Ahmet

AU - Hekimgil, Mine

AU - Ozsan, Nazan

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and monitoring of non-Hodgkin lymphomas (NHL). This chapter will deal with the current investigations focusing on the BM findings in secondary involvement of B-cell lymphomas. Recent World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues includes morphologic, immunophenotypic, cytogenetic, and molecular genetic data that define the disease entities [1]. Each entity described in this chapter will be discussed on the basis of a combination of these studies used in routine diagnosis of lymphoid malignancies. BM is occasionally examined for primary diagnosis of lymphoma patients, initial assessment of cytopenias of unknown etiology, especially when there's no accessible site of extramedullary disease or when surgical procedures are risky because of hazardous complications of anesthesia due to the general condition of the patients or diseases leading to bleeding diathesis. However, most BM examination, in the context of NHL, are performed to determine stage of disease, assessment of minimal residual disease (MRD) or relapse during follow-up, monitoring response to therapy, evaluation of hematopoietic reserve, and evaluation of pre-transplant status of patients.

AB - Bone marrow (BM) examinations are carried out as a cornerstone procedure for diagnosis, staging and monitoring of non-Hodgkin lymphomas (NHL). This chapter will deal with the current investigations focusing on the BM findings in secondary involvement of B-cell lymphomas. Recent World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues includes morphologic, immunophenotypic, cytogenetic, and molecular genetic data that define the disease entities [1]. Each entity described in this chapter will be discussed on the basis of a combination of these studies used in routine diagnosis of lymphoid malignancies. BM is occasionally examined for primary diagnosis of lymphoma patients, initial assessment of cytopenias of unknown etiology, especially when there's no accessible site of extramedullary disease or when surgical procedures are risky because of hazardous complications of anesthesia due to the general condition of the patients or diseases leading to bleeding diathesis. However, most BM examination, in the context of NHL, are performed to determine stage of disease, assessment of minimal residual disease (MRD) or relapse during follow-up, monitoring response to therapy, evaluation of hematopoietic reserve, and evaluation of pre-transplant status of patients.

UR - http://www.scopus.com/inward/record.url?scp=84949179134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949179134&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4174-7_11

DO - 10.1007/978-1-4471-4174-7_11

M3 - Chapter

AN - SCOPUS:84949179134

SN - 9781447141747

SN - 1447141733

SN - 9781447141730

VL - 9781447141747

SP - 191

EP - 221

BT - Bone Marrow Lymphoid Infiltrates: Diagnosis and Clinical Impact

PB - Springer-Verlag London Ltd

ER -